Opinion|Videos|May 12, 2025
Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management
Experts share their final thoughts on the discussion, offering key takeaways and reflections on the importance of lipoprotein(a) (Lp[a]) testing and its role in improving cardiovascular risk management
Advertisement
Video content above is prompted by the following:
Advertisement
Related to this article
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Independent VESALIUS-CV analysis finds evolocumab cost-effective at about 36% below the ACC/AHA benchmark for patients without prior MI or stroke.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
US Measles Outbreaks Cost Nearly $83 Million in 2026
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5